2 completed, 1 recruiting. 1 Early Phase 1, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Frontal Temporal Dementia (FTD): new trials by email Literature Review of Frontal Temporal Dementia (FTD) trials Research Report on Frontal Temporal Dementia (FTD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients Probiotic, Placebo - ALSFTD, ALS (Amyotrophic Lateral Sclerosis) | Not applicable | Recruiting | Centre hospitalier de l'Université de Montréal (CHUM) | 150 | 2024-01-01 | 2026-09-17 |
| Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies [18F]MNI-815 (MNI-815) - Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP) | Early Phase 1 | Completed | Molecular NeuroImaging | 7 | 2015-05-01 | 2016-12-16 |
| Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects [18F]T807 ([18F]MNI-777) - Alzheimer's Disease (AD), Parkinson's Disease (PD) | Phase 1 | Completed | Molecular NeuroImaging | 16 | 2014-02-01 | 2016-12-16 |
Alzheimer Disease (2) · Supranuclear Palsy, Progressive (2) · Amyotrophic Lateral Sclerosis (1) · Chronic Traumatic Encephalopathy (1) · Frontotemporal Dementia With Motor Neuron Disease (1) · Parkinson Disease (1) · Pick Disease of the Brain (1) · Tauopathies (1)
Central Nervous System Diseases (3) · Nervous System Diseases (3) · Neurodegenerative Diseases (3) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Cranial Nerve Diseases (2) · Dementia (2) · Eye Diseases (2) · Mental Disorders (2) · Movement Disorders (2) · Neurocognitive Disorders (2) · Neurologic Manifestations (2) · Ocular Motility Disorders (2) · Ophthalmoplegia (2) · Paralysis (2)
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · Probiotics (1) · florbetapir (1)
Molecular NeuroImaging (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1)
United States (2) · Canada (1)